US Supports Merck Development of Investigational COVID-19 Treatment With $356 Million

Merck MK-7110 (CD24Fc)is a first-in-class recombinant fusion protein that targets the innate immune system
two doctors working with face shield protection
New Jersey (Coronavirus Today)

The U.S. government announced Merck's agreement to support advanced development and large-scale manufacturing of the investigational therapeutic MK-7110 to treat hospitalized patients with severe or critical COVID-19.

The investigational therapeutic is a promising first-in-class fusion protein and immune modulator. Immune modulators have the potential to minimize the damaging effects of an overactive immune response to COVID-19. This overactive response can contribute to the severity of the illness.

“Our agreement with Merck is the latest example of how industry and government are coming together under Operation Warp Speed to move potential therapeutics all the way from development through to manufacturing, enabling faster distribution,” said the U.S. Department of the Health and Human Services (HHS) Secretary Alex Azar, in a press release. 

“More good news about COVID-19 therapeutics is constantly emerging.”

HHS and the Department of Defense (DOD) jointly stated the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, collaborated with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army Contracting Command (ACC-APG), to provide approximately $356 million to Merck. 

This funding allows for the development of MK-7110, including completing activities required to request Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and delivering up to 100,000 doses of MK-7110 by June 30, 2021.

The doses will be made available to the American public at no cost. However, there may be costs associated with hospitalization.

With this approach, doses will be packaged and ready to ship in the first half of 2021, in the event FDA determines MK-7110 meets the statutory criteria for issuance of a EUA. The federal government would allocate these doses to treat severe and critical COVID-19 patients using the same approach that has been used successfully to allocate supplies of other COVID-19 treatments. 

Interim analysis of a Phase 3 clinical trial in September 2020 indicated that patients who received a single dose of the therapeutic had a 60 percent greater chance of clinical recovery than those who received a placebo. Preliminary analysis also showed that the treatment potentially reduces the risk of respiratory failure or death by 50 percent compared to the standard of care. 

This Phase 3 study is still ongoing.

The U.S. HHS works to enhance and protect all Americans' health and well-being, providing for effective health and human services and fostering advances in medicine, public health, and social services.

CoronavirusToday publishes research-based news.